Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Jeff Fairman Biography and Net Worth

VP of Vaxcyte

Jeff has over 20 years of experience in the biotech arena having led the research at multiple platform companies that he co-founded resulting in multiple clinical candidates and approved vaccines and immunotherapeutics. Prior to Vaxcyte, Jeff was the founder and Vice President of Research at Juvaris BioTherapeutics, whose immunotherapeutic & vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. While at Juvaris, Jeff was the recipient of major grant funding from multiple sources, including NIH and NCI, supporting substantial pre-clinical programs and multiple clinical studies. He was responsible for research activities resulting in multiple clinical candidates and the approved animal health products. Prior to Juvaris, Jeff was the Director of Pharmacogenomics at Clingenix and Senior Scientist at Valentis. Dr. Fairman has a Ph.D. in Chemistry and his postdoctoral training was in the genetics of leukemia at MD Anderson Cancer Center. Jeff enjoys spending time with his wife and daughter and has put his amateur taekwondo career on hold, for the time being, to be courtside rooting for his daughter’s school and club volleyball teams.

What is Jeff Fairman's net worth?: The estimated net worth of Jeff Fairman is at least $17.83 million as of October 26th, 2022. Dr. Fairman owns 286,227 shares of Vaxcyte stock worth more than $17,834,804 as of April 23rd. This net worth estimate does not reflect any other assets that Dr. Fairman may own. Learn More about Jeff Fairman's net worth.
How old is Jeff Fairman?: Dr. Fairman is currently 60 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on Jeff Fairman's age.
How do I contact Jeff Fairman?: The corporate mailing address for Dr. Fairman and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Jeff Fairman's contact information.
Has Jeff Fairman been buying or selling shares of Vaxcyte?: Jeff Fairman has not been actively trading shares of Vaxcyte during the past quarter. Most recently, Jeff Fairman sold 10,000 shares of the business's stock in a transaction on Wednesday, October 26th. The shares were sold at an average price of $40.00, for a transaction totalling $400,000.00. Following the completion of the sale, the vice president now directly owns 286,227 shares of the company's stock, valued at $11,449,080. Learn More on Jeff Fairman's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Mikhail Eydelman (SVP), Jeff Fairman (VP), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 32 times. They sold a total of 266,096 shares worth more than $15,903,537.62. The most recent insider tranaction occured on April, 18th when CFO Andrew Guggenhime sold 8,000 shares worth more than $490,160.00. Insiders at Vaxcyte own 3.6% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 4/18/2024.

Jeff Fairman Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/26/2022	Sell	10,000	$40.00	$400,000.00	286,227
10/11/2022	Sell	5,000	$25.50	$127,500.00	296,227
8/4/2022	Sell	10,000	$25.50	$255,000.00	311,227
5/20/2022	Sell	4,112	$25.50	$104,856.00	321,227
5/5/2022	Sell	888	$25.80	$22,910.40	325,339
4/5/2022	Sell	5,000	$25.59	$127,950.00	16,629
3/11/2022	Sell	10,000	$25.50	$255,000.00
12/27/2021	Sell	4,750	$23.60	$112,100.00
12/16/2021	Sell	4,619	$22.50	$103,927.50
12/9/2021	Sell	131	$22.50	$2,947.50
10/26/2021	Sell	4,750	$22.69	$107,777.50
9/27/2021	Sell	4,750	$26.17	$124,307.50
8/26/2021	Sell	4,750	$25.38	$120,555.00	9,894
7/26/2021	Sell	4,750	$22.70	$107,825.00	9,894
6/28/2021	Sell	4,750	$24.37	$115,757.50	9,894
6/7/2021	Sell	9,500	$22.50	$213,750.00
3/26/2021	Sell	4,750	$23.88	$113,430.00	6,158
2/26/2021	Sell	4,750	$23.93	$113,667.50	6,158
1/26/2021	Sell	4,750	$25.27	$120,032.50	6,158

Jeff Fairman Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $62.31

$61.42

$62.56

50 Day Range

MA: $69.09

$60.62

$81.05

2 Week Range

Now: $62.31

$41.57

$82.04

Volume

150,022 shs

Average Volume

827,300 shs

Market Capitalization

$6.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

See how you can invest alongside him

Jeff Fairman Biography and Net Worth

What is Jeff Fairman's net worth?

How old is Jeff Fairman?

How do I contact Jeff Fairman?

Has Jeff Fairman been buying or selling shares of Vaxcyte?

Who are Vaxcyte's active insiders?

Are insiders buying or selling shares of Vaxcyte?